Notably, liposomal doxorubicin coupled with trastuzumab (Herceptin®), an anti-HER2 antibody, enhances drug delivery to HER2-positive breast cancer cells, improving therapeutic outcomes.77 Liang and colleagues78 utilized cationic liposomes decorated with peptide-p37 (CDO14) to administer siRNA in breast cancer cells overexpressing heat-shock-protein-gp96. This evidence concerns the gene HSP90B1 and breast cancer.